The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

Lay, Taco Bell, Uber Eats and others will vie to win over the more than 120 million viewers expected to tune in for the ...

Get ready for an onslaught of ads full of celebrities, cute animals and snack brands during breaks in the action at the Super ...

Disney’s Asad Ayaz discusses avoiding ad oversaturation, meeting industry changes and responding to brand controversies.

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls ... packages for our investment conferences and advertising on our websites and newsletters.